Iplik, Elif SinemErtugrul, BarisKozanoglu, IlknurBaran, YusufCakmakoglu, BediaBaran, Yusuf2023-11-182023-11-18201882008-38662008-387410.22038/IJBMS.2018.26152.6420https://doi.org/10.22038/IJBMS.2018.26152.6420http://standard-demo.gcris.com/handle/123456789/6981Kozanoglu, Ilknur/0000-0002-5268-1210; Cakmakoglu, Bedia/0000-0001-7960-9131; Bireller, Sinem/0000-0003-3465-1808; Ertugrul, Baris/0000-0003-3878-1829; Baran, Yusuf/0000-0002-1056-4673Objective(s): Colon cancer is risen up with its complex mechanism that directly impacts on its treatment as well as its common prevalence. Mesenchymal stem cells (MSCs) have been considered as a therapeutic candidate for conventional disease including cancer. In this research, we have focused on apoptotic effects of adipose tissue-derived MSCs in colon cancer. Materials and Methods: MSCs were obtained from adipose tissue and characterized by Flowcytometer using suitable antibodies. MSCs, HT-29, HCT-116, RKO and healthy cell line MRC5 were cultured by different seeding procedure. After cell viability assay, changes in caspase 3 enzyme activity and the level of phosphatidylserine were measured. Results: For cell viability assay, a 48 hr incubation period was chosen to seed all cells together. There was a 1.36-fold decrease in caspase 3 enzyme activity by co-treatment of RKO and MSCs in addition to 2.02-fold decrease in HT-29 and MSCs co-treatment, and 1.103-fold increase in HCT-116 and MSCs. The results demonstrated that HCT-116 led to the highest rate of apoptotic cell death (7.5%) compared with other cells. Conclusion: We suggest that MSCs might remain a new treatment option for cancer by its differentiation and repair capacity.eninfo:eu-repo/semantics/closedAccessApoptosisColon cancerStem cellsCell deathArticle215465468WOS:00043336010000429922425Q3Q3